Michael Lawrence Dougan, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colitis | 13 | 2023 | 1170 | 3.610 |
Why?
|
Immunotherapy | 34 | 2023 | 4445 | 3.490 |
Why?
|
Enterocolitis | 4 | 2023 | 102 | 2.560 |
Why?
|
Neoplasms | 38 | 2024 | 21683 | 1.920 |
Why?
|
Hepatitis | 2 | 2020 | 227 | 1.180 |
Why?
|
Inflammation | 11 | 2023 | 10638 | 1.050 |
Why?
|
Melanoma | 11 | 2023 | 5510 | 0.950 |
Why?
|
Gastrointestinal Diseases | 3 | 2020 | 1170 | 0.890 |
Why?
|
Inhibitor of Apoptosis Proteins | 5 | 2023 | 215 | 0.880 |
Why?
|
Receptors, Interleukin-2 | 2 | 2021 | 573 | 0.870 |
Why?
|
Melanoma, Experimental | 5 | 2020 | 561 | 0.860 |
Why?
|
Chylous Ascites | 1 | 2022 | 22 | 0.850 |
Why?
|
Tumor Microenvironment | 9 | 2023 | 3586 | 0.810 |
Why?
|
Eosinophilic Esophagitis | 2 | 2021 | 168 | 0.800 |
Why?
|
Interleukin-3 | 3 | 2019 | 444 | 0.780 |
Why?
|
Duodenitis | 1 | 2020 | 18 | 0.750 |
Why?
|
Interleukin-2 | 4 | 2022 | 1904 | 0.740 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2019 | 903 | 0.720 |
Why?
|
Mucositis | 1 | 2020 | 101 | 0.670 |
Why?
|
Gastritis | 3 | 2021 | 196 | 0.670 |
Why?
|
Immunoglobulin Fragments | 2 | 2018 | 84 | 0.670 |
Why?
|
Budesonide | 1 | 2019 | 154 | 0.660 |
Why?
|
Colitis, Microscopic | 1 | 2019 | 77 | 0.650 |
Why?
|
Interleukin-5 | 1 | 2019 | 273 | 0.650 |
Why?
|
Antibodies, Monoclonal | 9 | 2023 | 9274 | 0.600 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4149 | 0.570 |
Why?
|
Antineoplastic Agents | 9 | 2023 | 13695 | 0.560 |
Why?
|
Uveal Neoplasms | 1 | 2019 | 310 | 0.550 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2018 | 279 | 0.550 |
Why?
|
Celiac Disease | 2 | 2022 | 785 | 0.540 |
Why?
|
Cytokines | 9 | 2022 | 7322 | 0.540 |
Why?
|
Gastric Mucosa | 1 | 2019 | 599 | 0.530 |
Why?
|
T-Lymphocytes | 8 | 2023 | 10180 | 0.530 |
Why?
|
Myocarditis | 1 | 2023 | 771 | 0.530 |
Why?
|
Immunologic Memory | 1 | 2021 | 1348 | 0.500 |
Why?
|
Gastroenterology | 1 | 2020 | 536 | 0.490 |
Why?
|
Abdominal Pain | 1 | 2020 | 1063 | 0.460 |
Why?
|
Diarrhea | 1 | 2020 | 1348 | 0.440 |
Why?
|
Th17 Cells | 1 | 2019 | 766 | 0.440 |
Why?
|
Hydrocephalus | 1 | 2019 | 748 | 0.430 |
Why?
|
Immunotherapy, Adoptive | 4 | 2020 | 1270 | 0.430 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2019 | 4420 | 0.420 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2019 | 2915 | 0.410 |
Why?
|
Humans | 87 | 2024 | 744343 | 0.410 |
Why?
|
Immunologic Factors | 7 | 2021 | 1580 | 0.410 |
Why?
|
Autoimmune Diseases | 2 | 2020 | 2133 | 0.380 |
Why?
|
Pancreatic Neoplasms | 4 | 2023 | 5256 | 0.380 |
Why?
|
CD8-Positive T-Lymphocytes | 12 | 2023 | 4479 | 0.380 |
Why?
|
Glucocorticoids | 1 | 2020 | 2107 | 0.370 |
Why?
|
International Agencies | 5 | 2020 | 240 | 0.350 |
Why?
|
Stomach Neoplasms | 1 | 2019 | 1333 | 0.340 |
Why?
|
NF-kappa B | 5 | 2023 | 2499 | 0.340 |
Why?
|
Immunotherapy, Active | 1 | 2009 | 60 | 0.330 |
Why?
|
Animals | 40 | 2023 | 168757 | 0.330 |
Why?
|
Immunologic Surveillance | 1 | 2009 | 93 | 0.330 |
Why?
|
Receptors, Immunologic | 2 | 2020 | 1423 | 0.320 |
Why?
|
Endocrine System Diseases | 2 | 2020 | 248 | 0.310 |
Why?
|
Drug Eruptions | 2 | 2020 | 297 | 0.290 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7279 | 0.280 |
Why?
|
Severity of Illness Index | 9 | 2021 | 15540 | 0.280 |
Why?
|
Immunity | 3 | 2023 | 1012 | 0.270 |
Why?
|
Biopsy | 5 | 2020 | 6756 | 0.270 |
Why?
|
Immunity, Cellular | 2 | 2009 | 1607 | 0.270 |
Why?
|
Drug Delivery Systems | 1 | 2017 | 2219 | 0.270 |
Why?
|
Mice | 29 | 2023 | 81183 | 0.260 |
Why?
|
Intestinal Mucosa | 3 | 2020 | 3036 | 0.250 |
Why?
|
Viral Load | 3 | 2022 | 3299 | 0.240 |
Why?
|
History, 21st Century | 5 | 2020 | 1534 | 0.240 |
Why?
|
Societies, Medical | 6 | 2020 | 3743 | 0.240 |
Why?
|
Acids | 1 | 2004 | 127 | 0.240 |
Why?
|
Diglycerides | 1 | 2023 | 176 | 0.230 |
Why?
|
Recombinant Proteins | 4 | 2023 | 6622 | 0.230 |
Why?
|
Cancer Vaccines | 5 | 2020 | 1023 | 0.220 |
Why?
|
Respiratory Muscles | 1 | 2023 | 139 | 0.220 |
Why?
|
Mitochondrial Proteins | 2 | 2019 | 996 | 0.210 |
Why?
|
Retrospective Studies | 14 | 2023 | 77449 | 0.210 |
Why?
|
Interferon-gamma | 4 | 2023 | 3206 | 0.210 |
Why?
|
Colonoscopy | 2 | 2020 | 1367 | 0.200 |
Why?
|
Disease Models, Animal | 9 | 2020 | 18029 | 0.200 |
Why?
|
Phagocytosis | 3 | 2017 | 1539 | 0.200 |
Why?
|
Amides | 1 | 2004 | 459 | 0.200 |
Why?
|
Inflammatory Bowel Diseases | 3 | 2020 | 2425 | 0.190 |
Why?
|
Receptors, Antigen, T-Cell | 6 | 2023 | 2540 | 0.190 |
Why?
|
Middle Aged | 21 | 2022 | 213383 | 0.190 |
Why?
|
Cell Line, Tumor | 8 | 2023 | 16689 | 0.190 |
Why?
|
Signal Transduction | 8 | 2023 | 23403 | 0.190 |
Why?
|
Appendectomy | 1 | 2023 | 401 | 0.180 |
Why?
|
Hospitalization | 6 | 2021 | 10262 | 0.180 |
Why?
|
Palliative Care | 5 | 2020 | 3493 | 0.180 |
Why?
|
Microvilli | 1 | 2020 | 241 | 0.180 |
Why?
|
Aged | 19 | 2022 | 163280 | 0.180 |
Why?
|
Receptors, Interleukin-5 | 1 | 2019 | 19 | 0.180 |
Why?
|
Receptors, Interleukin-3 | 1 | 2019 | 30 | 0.170 |
Why?
|
Phagocytes | 1 | 2021 | 297 | 0.170 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 224 | 0.170 |
Why?
|
Lentivirus | 1 | 2022 | 501 | 0.170 |
Why?
|
Multigene Family | 2 | 2020 | 1102 | 0.170 |
Why?
|
Peptides | 2 | 2023 | 4409 | 0.170 |
Why?
|
Male | 27 | 2022 | 350118 | 0.170 |
Why?
|
Gadolinium | 1 | 2024 | 952 | 0.160 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 110 | 0.160 |
Why?
|
Mice, Inbred C57BL | 9 | 2023 | 21827 | 0.160 |
Why?
|
Female | 30 | 2023 | 380194 | 0.160 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 322 | 0.160 |
Why?
|
Glutens | 1 | 2021 | 230 | 0.160 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2020 | 431 | 0.160 |
Why?
|
Molecular Targeted Therapy | 3 | 2019 | 2727 | 0.160 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 20129 | 0.160 |
Why?
|
Interleukin-15 | 1 | 2019 | 184 | 0.160 |
Why?
|
Antigens, Neoplasm | 4 | 2023 | 1988 | 0.160 |
Why?
|
Virus Internalization | 1 | 2022 | 501 | 0.160 |
Why?
|
Molecular Mimicry | 1 | 2019 | 201 | 0.160 |
Why?
|
Milk | 1 | 2021 | 450 | 0.160 |
Why?
|
Neutropenia | 1 | 2023 | 895 | 0.150 |
Why?
|
Antigens, Viral | 1 | 2022 | 1035 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 538 | 0.150 |
Why?
|
Receptors, Chemokine | 1 | 2020 | 669 | 0.150 |
Why?
|
Mice, Knockout | 7 | 2019 | 14557 | 0.140 |
Why?
|
Biomimetics | 1 | 2018 | 172 | 0.140 |
Why?
|
Immune Tolerance | 2 | 2020 | 2258 | 0.140 |
Why?
|
Adipocytes, Brown | 1 | 2017 | 144 | 0.140 |
Why?
|
Infusions, Intravenous | 1 | 2021 | 2274 | 0.140 |
Why?
|
Skin Neoplasms | 3 | 2020 | 5686 | 0.140 |
Why?
|
Adaptive Immunity | 2 | 2018 | 713 | 0.140 |
Why?
|
Autoimmunity | 2 | 2021 | 1349 | 0.130 |
Why?
|
Myeloid Cells | 1 | 2020 | 810 | 0.130 |
Why?
|
Immunomodulation | 3 | 2019 | 541 | 0.130 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1475 | 0.130 |
Why?
|
Hydrazines | 1 | 2017 | 226 | 0.130 |
Why?
|
Colon | 2 | 2020 | 1772 | 0.130 |
Why?
|
Prognosis | 5 | 2022 | 29063 | 0.130 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 1366 | 0.120 |
Why?
|
Neoplasms, Experimental | 2 | 2019 | 1276 | 0.120 |
Why?
|
Natural Killer T-Cells | 1 | 2017 | 316 | 0.120 |
Why?
|
Sphingolipids | 1 | 2015 | 159 | 0.120 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2017 | 520 | 0.120 |
Why?
|
Drug Resistance | 1 | 2020 | 1609 | 0.120 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4851 | 0.120 |
Why?
|
Intestine, Small | 1 | 2020 | 1241 | 0.120 |
Why?
|
Rheumatic Diseases | 1 | 2020 | 592 | 0.120 |
Why?
|
Adenocarcinoma | 1 | 2011 | 6364 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7913 | 0.110 |
Why?
|
Drug Design | 1 | 2019 | 1076 | 0.110 |
Why?
|
Physician's Role | 1 | 2020 | 943 | 0.110 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3129 | 0.110 |
Why?
|
Language | 1 | 2022 | 1471 | 0.110 |
Why?
|
Double-Blind Method | 3 | 2021 | 12026 | 0.110 |
Why?
|
Apoptosis | 4 | 2023 | 9727 | 0.110 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2016 | 693 | 0.110 |
Why?
|
Candidiasis | 1 | 2015 | 366 | 0.110 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2018 | 1157 | 0.110 |
Why?
|
Trypsin | 1 | 2013 | 511 | 0.110 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.110 |
Why?
|
Candida albicans | 1 | 2015 | 394 | 0.110 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.110 |
Why?
|
Occupational Diseases | 1 | 2020 | 1471 | 0.110 |
Why?
|
Nanoparticles | 1 | 2024 | 1905 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2017 | 1375 | 0.100 |
Why?
|
Neoplasm Transplantation | 2 | 2017 | 2085 | 0.100 |
Why?
|
Adipose Tissue, Brown | 1 | 2017 | 757 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1855 | 0.100 |
Why?
|
Radiation Chimera | 1 | 2011 | 223 | 0.100 |
Why?
|
Triazoles | 1 | 2017 | 911 | 0.100 |
Why?
|
Hematopoiesis | 2 | 2019 | 2072 | 0.100 |
Why?
|
Immunocompetence | 1 | 2011 | 137 | 0.100 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6489 | 0.100 |
Why?
|
Equipment Design | 1 | 2019 | 3582 | 0.100 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1622 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6538 | 0.090 |
Why?
|
Autocrine Communication | 1 | 2011 | 171 | 0.090 |
Why?
|
Lung Diseases | 1 | 2020 | 1886 | 0.090 |
Why?
|
Adult | 11 | 2021 | 214055 | 0.090 |
Why?
|
Camelids, New World | 2 | 2020 | 20 | 0.090 |
Why?
|
Kidney Diseases | 1 | 2020 | 2149 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2021 | 2987 | 0.080 |
Why?
|
Bacteria | 1 | 2019 | 2114 | 0.080 |
Why?
|
Aminopyridines | 2 | 2023 | 542 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4215 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2017 | 13102 | 0.080 |
Why?
|
Diagnosis, Differential | 2 | 2020 | 12959 | 0.080 |
Why?
|
Wound Healing | 1 | 2019 | 2785 | 0.080 |
Why?
|
Anemia | 1 | 2017 | 1506 | 0.080 |
Why?
|
Neoplasm Staging | 2 | 2019 | 11031 | 0.080 |
Why?
|
Cell Survival | 1 | 2018 | 5882 | 0.080 |
Why?
|
Homeostasis | 2 | 2017 | 3340 | 0.080 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2011 | 547 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3218 | 0.070 |
Why?
|
Interleukin-6 | 2 | 2020 | 3200 | 0.070 |
Why?
|
STAT3 Transcription Factor | 1 | 2011 | 873 | 0.070 |
Why?
|
Vaccination | 1 | 2019 | 3278 | 0.070 |
Why?
|
Mice, Inbred BALB C | 2 | 2017 | 6386 | 0.070 |
Why?
|
Milk Proteins | 1 | 2007 | 169 | 0.070 |
Why?
|
Host-Pathogen Interactions | 1 | 2015 | 1477 | 0.070 |
Why?
|
Vitamin D | 1 | 2020 | 3223 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2020 | 3557 | 0.070 |
Why?
|
Tumor Escape | 1 | 2009 | 349 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2018 | 2958 | 0.070 |
Why?
|
Immunoglobulin G | 1 | 2018 | 4560 | 0.070 |
Why?
|
Young Adult | 3 | 2021 | 56430 | 0.070 |
Why?
|
Paclitaxel | 2 | 2023 | 1708 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11524 | 0.070 |
Why?
|
Risk Factors | 2 | 2023 | 72290 | 0.060 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1836 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2021 | 57776 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5535 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7474 | 0.060 |
Why?
|
Oncogene Proteins | 1 | 2009 | 749 | 0.060 |
Why?
|
Treatment Outcome | 6 | 2021 | 63114 | 0.060 |
Why?
|
Career Choice | 1 | 2011 | 744 | 0.060 |
Why?
|
Research Design | 1 | 2020 | 5987 | 0.060 |
Why?
|
MAP Kinase Signaling System | 1 | 2011 | 1526 | 0.060 |
Why?
|
Child | 2 | 2022 | 77709 | 0.060 |
Why?
|
Antigen-Presenting Cells | 1 | 2007 | 973 | 0.060 |
Why?
|
Transforming Growth Factors | 1 | 2023 | 76 | 0.060 |
Why?
|
Cell Differentiation | 2 | 2019 | 11483 | 0.060 |
Why?
|
Adjuvants, Immunologic | 1 | 2009 | 1000 | 0.060 |
Why?
|
Antigens, Surface | 1 | 2007 | 1663 | 0.050 |
Why?
|
Perforin | 1 | 2023 | 168 | 0.050 |
Why?
|
Breast Neoplasms | 2 | 2021 | 20822 | 0.050 |
Why?
|
Brucella abortus | 1 | 2001 | 12 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2020 | 2988 | 0.050 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2001 | 122 | 0.050 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2007 | 1116 | 0.050 |
Why?
|
Bone Marrow Transplantation | 1 | 2009 | 2765 | 0.050 |
Why?
|
Interleukin-12 | 1 | 2023 | 579 | 0.050 |
Why?
|
Albumins | 1 | 2023 | 569 | 0.050 |
Why?
|
Enteritis | 1 | 2021 | 165 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 141 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 648 | 0.050 |
Why?
|
Lymphocyte Activation | 3 | 2020 | 5524 | 0.050 |
Why?
|
Radioimmunotherapy | 1 | 2020 | 91 | 0.040 |
Why?
|
Molecular Structure | 1 | 2004 | 1899 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 132 | 0.040 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2019 | 48 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2024 | 2327 | 0.040 |
Why?
|
Insulin-Secreting Cells | 1 | 2007 | 891 | 0.040 |
Why?
|
Vaccines, Subunit | 1 | 2020 | 168 | 0.040 |
Why?
|
Purines | 1 | 2023 | 594 | 0.040 |
Why?
|
Receptors, CXCR3 | 1 | 2020 | 237 | 0.040 |
Why?
|
Breast Neoplasms, Male | 1 | 2021 | 210 | 0.040 |
Why?
|
Tomography | 1 | 2021 | 390 | 0.040 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2022 | 548 | 0.040 |
Why?
|
Eligibility Determination | 1 | 2022 | 403 | 0.040 |
Why?
|
Off-Label Use | 1 | 2020 | 169 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2022 | 8642 | 0.040 |
Why?
|
Medical Oncology | 2 | 2020 | 2265 | 0.040 |
Why?
|
United States | 3 | 2021 | 69872 | 0.040 |
Why?
|
Granzymes | 1 | 2020 | 271 | 0.040 |
Why?
|
Carcinoma, Small Cell | 1 | 2020 | 420 | 0.040 |
Why?
|
Hyperglycemia | 1 | 2007 | 1373 | 0.040 |
Why?
|
Graft Rejection | 1 | 2011 | 4397 | 0.040 |
Why?
|
Massachusetts | 2 | 2021 | 8663 | 0.040 |
Why?
|
Colonic Neoplasms | 2 | 2020 | 2541 | 0.040 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 310 | 0.040 |
Why?
|
Cross-Linking Reagents | 1 | 2020 | 694 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2020 | 5974 | 0.040 |
Why?
|
Viremia | 1 | 2020 | 736 | 0.040 |
Why?
|
Eosinophilia | 1 | 2021 | 541 | 0.040 |
Why?
|
Protein Stability | 1 | 2019 | 557 | 0.040 |
Why?
|
Eosinophils | 1 | 2021 | 955 | 0.040 |
Why?
|
Kinetics | 1 | 2004 | 6473 | 0.040 |
Why?
|
Pandemics | 3 | 2021 | 8388 | 0.040 |
Why?
|
Antigens | 1 | 2022 | 1466 | 0.030 |
Why?
|
Chemokines | 1 | 2020 | 970 | 0.030 |
Why?
|
Chromatography, Thin Layer | 1 | 2015 | 223 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2021 | 850 | 0.030 |
Why?
|
Drug Synergism | 1 | 2020 | 1792 | 0.030 |
Why?
|
Autoantigens | 1 | 2020 | 892 | 0.030 |
Why?
|
Organ Culture Techniques | 1 | 2017 | 813 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 2007 | 0.030 |
Why?
|
Stomach | 1 | 2019 | 697 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15165 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2618 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1531 | 0.030 |
Why?
|
Crystallography, X-Ray | 1 | 2019 | 2011 | 0.030 |
Why?
|
Disease Progression | 2 | 2020 | 13284 | 0.030 |
Why?
|
Headache | 1 | 2021 | 1226 | 0.030 |
Why?
|
Cohort Studies | 3 | 2021 | 40561 | 0.030 |
Why?
|
Ligands | 1 | 2020 | 3282 | 0.030 |
Why?
|
Adolescent | 1 | 2021 | 85781 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2011 | 5442 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1486 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3527 | 0.030 |
Why?
|
Thymus Gland | 1 | 2017 | 1267 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2015 | 809 | 0.030 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2007 | 3336 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 4386 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 5751 | 0.030 |
Why?
|
Lymphocytes | 1 | 2020 | 2617 | 0.030 |
Why?
|
Antibody Formation | 1 | 2017 | 1402 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1782 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 2959 | 0.030 |
Why?
|
RNA, Viral | 1 | 2020 | 2902 | 0.030 |
Why?
|
Immunization | 1 | 2016 | 1256 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4204 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 1838 | 0.020 |
Why?
|
Internship and Residency | 1 | 2011 | 5788 | 0.020 |
Why?
|
Piperazines | 1 | 2021 | 2488 | 0.020 |
Why?
|
Binding Sites | 1 | 2019 | 6114 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2531 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2183 | 0.020 |
Why?
|
Macrophages | 2 | 2021 | 5655 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2020 | 3176 | 0.020 |
Why?
|
Inpatients | 1 | 2021 | 2518 | 0.020 |
Why?
|
Phosphorylation | 1 | 2020 | 8436 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2825 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2021 | 10943 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2021 | 3589 | 0.020 |
Why?
|
Models, Molecular | 1 | 2019 | 5456 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2459 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2015 | 2203 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2670 | 0.020 |
Why?
|
Neutrophils | 1 | 2020 | 3719 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13408 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3679 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2020 | 12072 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2019 | 13815 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14722 | 0.020 |
Why?
|
Computer Simulation | 1 | 2019 | 6196 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12788 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15076 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13989 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2015 | 2725 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2013 | 2969 | 0.020 |
Why?
|
Antigens, Differentiation | 1 | 2007 | 927 | 0.010 |
Why?
|
Internal Medicine | 1 | 2011 | 1009 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2007 | 1866 | 0.010 |
Why?
|
Mice, Inbred NOD | 1 | 2007 | 1878 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 19229 | 0.010 |
Why?
|
Chemokine CCL3 | 1 | 2001 | 83 | 0.010 |
Why?
|
Chemokine CCL4 | 1 | 2001 | 128 | 0.010 |
Why?
|
Data Collection | 1 | 2011 | 3341 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6234 | 0.010 |
Why?
|
Cell Line | 1 | 2015 | 15997 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9734 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 25043 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2018 | 9239 | 0.010 |
Why?
|
Membrane Fusion | 1 | 2001 | 273 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 19905 | 0.010 |
Why?
|
Quantitative Trait Loci | 1 | 2007 | 2019 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4026 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 53288 | 0.010 |
Why?
|
Pediatrics | 1 | 2011 | 3475 | 0.010 |
Why?
|
Hot Temperature | 1 | 2001 | 1354 | 0.010 |
Why?
|
AIDS Vaccines | 1 | 2001 | 938 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2001 | 2216 | 0.010 |
Why?
|
Monocytes | 1 | 2001 | 2596 | 0.010 |
Why?
|
HIV-1 | 1 | 2001 | 6939 | 0.000 |
Why?
|